思摩爾國際(06969.HK):冀保持研發開支佔比達10%以上 料下半年毛利率下降
思摩爾國際(06969.HK)副總裁兼首席財務官王貴升表示,上半年毛利率按年跌11.7個百分點,至36.2%,主要是受到一次性產品等影響,惟仍預料因產品結構變化影響令下半年毛利率下降。
他表示,上半年集團研發開支為6.15億元人民幣,預料下半年研發開支較上半年有所增加,惟增加幅度不大,冀望未來繼續保持佔總收入的10%以上。
他表示,自上年11月起,因監管問題而拖累內地市場收入增長,但由今年1月起已有增長,料下半年會保持上升趨勢。
總裁陳志平表示,將陸續向海外市場推出更多具差異化優勢的創新一次性產品,推動收入的增長;同時,又指集團在霧化醫療領域的研發正穩步推進中,下半年將繼續按既定計劃,開展各項醫藥研發項目的研究。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.